(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.
Apr 11, 2016
0
0
Specific immune cells, known as T lymphocytes, have to be activated so that the body can develop long-term protection against infections. Previously, it was believed that this process only took place in the lymph nodes and ...
Sep 5, 2014
0
0
A new study demonstrates that iPSC have the potential to differentiate into multiple lineages of functional lymphocytes, including CD4+ T cells, B cells, and natural killer cells, without bias. The ability to generate truly ...
Mar 28, 2016
0
1
Patients with advanced chronic lymphocytic leukemia (CLL) often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there ...
Aug 5, 2013
0
0
No one likes clingy people, but "clingy" blood platelets may offer hope for millions of people with rheumatoid arthritis. According to new research findings published in The Journal of Leukocyte Biology, a sub population ...
Aug 29, 2013
0
0
The process of blood cell development, known as hematopoiesis, gives rise to numerous different immune cell subtypes. Each of these in turn matures through a stepwise process governed by the action of transcription factors—specialized ...
Nov 22, 2012
0
0
An Inserm team in Dijon directed by François Ghiringhelli is to publish an article this week in the Nature Medicine review. The article suggests that two chemotherapy drugs frequently used to treat digestive and breast cancers ...
Dec 4, 2012
0
0
The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American ...
Dec 8, 2014
0
0
Treating B cell malignancies with the patients' own T cells modified so as to target specific B cell markers has shown clinical success.
Jun 6, 2016
0
1
A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego identifies inherited genetic mutations in the gene IKZF1 that confer a higher ...
Dec 6, 2016
0
0
